Advertisement

Topics

Latest "Mifepristone Cushing Syndrome" News Stories

12:37 EDT 18th August 2017 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 2,200+

Extremely Relevant

Cushing's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Report Updated: 01022017] Prices from USD $4950

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 7MM Reports provides an overview of the disease and global market size of the Cushing Syndrome for the 7MM. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of C...


Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 US [Updated: 30052017] Prices from USD $2083

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 US Reports provides an overview of the disease and global market size of the Cushing Syndrome for the US. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of Cus...

Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 EU5 [Updated: 30052017] Prices from USD $2083

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 EU5 Reports provides an overview of the disease and global market size of the Cushing Syndrome for the EU5. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of C...


Cushing's Syndrome Market Insights, Epidemiology and Market Forecast2023 [Updated: 30052017] Prices from USD $4208

DelveInsight's Cushing Syndrome Market Insights, Epidemiology and Market Forecast 2023 7MM Reports provides an overview of the disease and global market size of the Cushing Syndrome for the 7MM. It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Cushing Syndrome from 20102023. According to Publisher, the forecasted patient population of C...

NIH finding may lead to therapies that prevent Cushing syndrome

  A small study by researchers at the National Institutes of Health (NIH) suggests that mutations in the gene CABLES1 may lead to Cushing syndrome, a rare disorder in which the body overproduces the stress hormone cortisol. The study appears online in Endocrine-Related Cancer. The excess cortisol found in Cushing syndrome can result from certain […] The post NIH finding may lead to therapie...

Cushing's Syndrome Epidemiology Insights to 2025 [Report Updated: 10072017] Prices from USD $2950

DelveInsight Cushing's Syndrome Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Cushing's Syndrome in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Cushing's Syndrome prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevail...

Cushing's Syndrome Epidemiology Insights to 2023 [Report Updated: 01012017] Prices from USD $2750

DelveInsight Cushing's Syndrome Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Cushing's Syndrome in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Cushing's Syndrome prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevaili...

Cushing's Syndrome Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10072017] Prices from USD $5750

DelveInsight's Cushing's Syndrome Market Insights, Epidemiology and Market Forecast 2025 Reports provides an overview of the disease and global market size of the Cushing's Syndrome for the 7MM United States, Germany, France, Italy, Spain and UK. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Cushing's Syndrome forecasted market share for ten y...

Cushing's Syndrome Epidemiology Forecast To 2023 [Updated: 31052017] Prices from USD $2338

DelveInsight Cushing's Syndrome Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Cushing's Syndrome in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Cushing's Syndrome prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevaili...

Potential Genetic Cause of Cushing Syndrome Found

A recent study suggests that mutations in the gene Cdk5 And Abl Enzyme Substrate 1 (CABLES1) may lead to Cushing...

New NIH study reveals mutations in gene CABLES1 may lead to Cushing syndrome

A new study conducted by researchers at the National Institutes of Health (NIH) shows that mutations in the gene CABLES1 may lead to Cushing syndrome, a rare disorder that makes the human body produce excess stress hormone cortisol.

Drug trial begins for Cushing’s syndrome therapy

Participant enrollment has concluded for a phase 3 trial investigating the safety and efficacy of levoketoconazole, a cortisol synthesis inhibitor, for the treatment of endogenous Cushing’s syndrome, according to a press release from Strongbridge Biopharma, the drug’s developer. The single-arm, open-label SONICS study will include the 90 enrolled participants and may allow a small number of ot...

Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress

MENLO PARK, CA -- (Marketwired) -- 05/04/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that presentations about hypercortisolism and mifepristone's role in treating that disor...

Relevant

NIH researchers find potential genetic cause of Cushing syndrome

Finding may lead to therapies that prevent pituitary tumor recurrence.

Strongbridge Biopharma Completes Target Enrollment Of 90 Patients In The Phase III SONICS Study Evaluating RECORLEV (Levoketoconazole) In Endogenous Cushing???s Syndrome

  Life Sciences Jobs   ...

Millendo commences Phase II trial of ATR-101 to treat endogenous CS

US-based biopharmaceutical firm Millendo Therapeutics has commenced a Phase II clinical trial of ATR-101 for the treatment of patients with endogenous cushing’s syndrome (CS).

What's Behind Corcept's (CORT) Valuation Dip - June 8, 2017

On Thursday, June 8, 2017, Corcept Therapeutics (CORT) had a difficult trading day.  There were some large trades in the morning that sent the valuation careening from its previous close of $12.48 to just about 11.25. It closed at $11.51.Retail became concerned and rumor ran faster than a barking dog. But we have been waiting for this selling to occur. CORT had a valuation dip in late Novembe...

Why did Corcept's (CORT) Share Price Rise?

IntroductionWe recently fielded multiple inquiries about Corcept Therapeutics (CORT): what’s the reason(s) for its increased valuation?Recent Price ActionMay 1, 2017: Corcept released its Q1-2017 results and provided upward guidance for sales. The company also added $4M to its cash position while launching important new clinical studies. 

STRESS : L'excès de cortisol chahute notre ADN - Scientific Reports

Des concentrations élevées de l'hormone du stress, le cortisol, dans le corps affectent des processus clés de l'ADN et augmentent le risque de conséquences psychologiques à long terme. Cette étude de l'Université de Göteborg menée auprès de patients atteints du syndrome de Cushing (associé à une surproduction substan...

Understanding Alzheimer's disease and Down syndrome

People who have Down syndrome may develop Alzheimer's disease at a younger age than people without Down syndrome. Recently, however, research showed that some people with Down syndrome might not develop dementia at all. Doctors and researchers are still trying to learn why some people with Down syndrome develop dementia, either earlier or later, while others don't.

Medical News Today: Empty nose syndrome: Causes, symptoms, and treatment

What is empty nose syndrome, what are the main causes, and how is empty nose syndrome diagnosed? Learn about empty nose syndrome and turbinate surgery.

“What Kind of Society Do You Want to Live in?”: Inside the Country Where Down Syndrome Is Disappearing

(CBS News) – With the rise of prenatal screening tests across Europe and the United States, the number of babies born with Down syndrome has significantly decreased, but few countries have come as close to eradicating Down syndrome births as … Read More

Medical News Today: Wallenberg's syndrome: Symptoms, causes, and treatment

What is Wallenberg’s syndrome and who may be most at risk? Learn about the causes of Wallenberg’s syndrome, how it is diagnosed, and ongoing research.

Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update

MENLO PARK, CA -- (Marketwired) -- 05/01/17 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its financial results for the quarter e...

WomanCare Global to Distribute Mifepristone in Europe and Africa

Increasing access to mifepristone to improve women's reproductive health choices LONDON, Feb. 9, 2012 /PRNewswire-USNewswire/ -- WomanCare Global announced today that mifepristone has been added to their reproductive healthcare portfolio.  Through an agreement with Linepharma, WomanCare Global will provide sales, marketing, provider training and distribution of mifepristone i...


Quick Search
Advertisement
 

News Quicklinks